Last edition
News about "Basilea Pharmaceutica"
BARDA Boosts Funding for Basilea's Investigational Oral Antibiotic Targeting Drug-Resistant UTIs
Basilea Pharmaceutica has secured an additional USD 5.4 million from BARDA to accelerate the development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil, a potential treatment for complicated urinary tract infections caused by multidrug-resistant Gram-negative pathogens.
Basilea Pharmaceutica | 06/08/2026 | By News Bureau | 106
Prokaryotics, Basilea Partner to Develop First-in-Class Broad-Spectrum Antifungal
Partnership between Prokaryotics and Basilea will develop broad-spectrum antifungal treatment that targets life-threatening invasive fungal infections.
Basilea Pharmaceutica | 07/01/2026 | By News Bureau | 180
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy